Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 1

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 1
---
 indemnify the Agent against
certain liabilities, including liabilities under the Securities Act, or to contribute payments that the Agent may be required to make
because of such liabilities.

As of September 4, 2025, our public float, which is equal to the aggregate
market value of our outstanding voting and non-voting common stock,, held by non-affiliates, was approximately $10,546,611 million, based
on 4,104,469 shares of outstanding common stock, of which approximately 4,040,847 shares were held by non-affiliates, and a closing sale
price of our common stock of $2.61 on that date. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities
in a public primary offering with a value exceeding more than one-third of our public float in any 12-calendar-month period so long as our public
float remains below $75.0 million.

Investing in our common stock involves risks. You should carefully consider all of the information set forth in this prospectus supplement and the accompanying base prospectus, and in the reports we file with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended, incorporated by reference in this prospectus supplement before deciding to invest in our common stock. Please see “Risk Factors” beginning on page S-13 and in the documents incorporated by reference into this prospectus supplement to read about factors you should consider before buying our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>H.C. Wainwright & Co.

Prospectus dated September 5, 2025

TABLE OF CONTENTS

Prospectus Supplement</div>

|                                                      | Page  |
| About this prospectus supplement                     | S-ii  |
| Cautionary Note Regarding Forward-Looking Statements | S-iii |
| Prospectus Summary                                   | S-1   |
| Risk Factors                                         | S-19  |
| Use of Proceeds                                      | S-22  |
| Dividend Policy                                      | S-23  |
| Dilution                                             | S-24  |
| Plan of Distribution                                 | S-25  |
| Legal Matters                                        | S-26  |
| Experts                                              | S-26